Caltag clone experiences
Rex Hensley, GS12, PSCCI (hensley@WHMC-LAFB.AF.MIL)
Thu, 8 May 1997 09:08:52 -0500
Hi fellow flowers,
We are in a cost containment environment and are currently evaluating
changing our leukemia/lymphoma panel to utilize all Caltag monoclonal
antibodies. The clones of interest are CD20, CD5, CD7, CD3, CD4, CD8, CD10,
CD19, CD25, CD11c, CD16, CD56, CD14, CD23, with CD45(cy5 tandem). Since it is
inherently difficult to properly evaluate these clones on "live" specimens,
does anyone have any experience with them? I am particularly interested in
their performance characteristics, and how well they match their appropriate
isotypic controls. Other than using "live" specimens what is the best way for
someone to avoid the pitfalls of a major change in monoclonal antibody
suppliers? Any input would be greatly appreciated. Thank you.
Rex E. Hensley, GS-12, DAF
Technical Supervisor Cellular Immunology
Wilford Hall Medical Center
Lackland AFB, Texas
hensley@whmc-lafb.af.mil